Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire

Robert P. Baughman; Elyse E. Lower; Mindy Buchanan; Paola Rottoli; Marjolein Drent; Jacobo Sellares; Michelle Terwiel; Marjon Elfferich; Joel Francesqui; Maria Rita Barriuso Cabrerizo; Nadera Sweiss; Filippo Martone; Tamara Al-Hakim; Marc A. Judson

doi:10.36141/svdld.v37i4.10726

Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire

Robert P. Baughman^*, Elyse E. Lower, Mindy Buchanan, Paola Rottoli, Marjolein Drent, Jacobo Sellares, Michelle Terwiel, Marjon Elfferich, Joel Francesqui, Maria Rita Barriuso Cabrerizo, Nadera Sweiss, Filippo Martone, Tamara Al-Hakim, Marc A. Judson

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

11 Citations (Web of Science)

Abstract

Background: It has been suggested that sarcoidosis patients, especially those on immunosuppressive medications, are at increased risk for COVID-19 infection and more severe disease. Methods: A questionnaire was developed in four languages (English, Dutch, Italian, and Spanish). The questionnaire queried whether patients had been infected with COVID-19 and outcome of the infection. Risk factors for COVID-19 infection were collected. Results: A total of 5200 sarcoidosis patients completed the questionnaire with 116 (2.23%) reporting infection and 18 (15.8%) required hospitalization. Increased hazard ratio (HR) for COVID-19 infection were seen for those with a COVID-19 infected roommate (HR=27.44, p

Original language	English
Article number	2020009
Number of pages	12
Journal	Sarcoidosis Vasculitis and Diffuse Lung Diseases
Volume	37
Issue number	4
DOIs	https://doi.org/10.36141/svdld.v37i4.10726
Publication status	Published - 2020

Keywords

COVID-19
sarcoidosis
immunosuppression

Access to Document

10.36141/svdld.v37i4.10726Licence: CC BY-NC

Cite this

Baughman, R. P., Lower, E. E., Buchanan, M., Rottoli, P., Drent, M., Sellares, J., Terwiel, M., Elfferich, M., Francesqui, J., Barriuso Cabrerizo, M. R., Sweiss, N., Martone, F., Al-Hakim, T., & Judson, M. A. (2020). Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire . Sarcoidosis Vasculitis and Diffuse Lung Diseases, 37(4), [2020009]. https://doi.org/10.36141/svdld.v37i4.10726

@article{c7872fa6e49146a7854519fac53447f2,

title = "Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire ",

abstract = "Background: It has been suggested that sarcoidosis patients, especially those on immunosuppressive medications, are at increased risk for COVID-19 infection and more severe disease. Methods: A questionnaire was developed in four languages (English, Dutch, Italian, and Spanish). The questionnaire queried whether patients had been infected with COVID-19 and outcome of the infection. Risk factors for COVID-19 infection were collected. Results: A total of 5200 sarcoidosis patients completed the questionnaire with 116 (2.23%) reporting infection and 18 (15.8%) required hospitalization. Increased hazard ratio (HR) for COVID-19 infection were seen for those with a COVID-19 infected roommate (HR=27.44, p",

keywords = "COVID-19, sarcoidosis, immunosuppression",

author = "Baughman, {Robert P.} and Lower, {Elyse E.} and Mindy Buchanan and Paola Rottoli and Marjolein Drent and Jacobo Sellares and Michelle Terwiel and Marjon Elfferich and Joel Francesqui and {Barriuso Cabrerizo}, {Maria Rita} and Nadera Sweiss and Filippo Martone and Tamara Al-Hakim and Judson, {Marc A.}",

year = "2020",

doi = "10.36141/svdld.v37i4.10726",

language = "English",

volume = "37",

journal = "Sarcoidosis Vasculitis and Diffuse Lung Diseases",

issn = "1124-0490",

publisher = "Mattioli 1885 S.p.A.",

number = "4",

}

Baughman, RP, Lower, EE, Buchanan, M, Rottoli, P, Drent, M, Sellares, J, Terwiel, M, Elfferich, M, Francesqui, J, Barriuso Cabrerizo, MR, Sweiss, N, Martone, F, Al-Hakim, T & Judson, MA 2020, 'Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire ', Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 37, no. 4, 2020009. https://doi.org/10.36141/svdld.v37i4.10726

TY - JOUR

T1 - Risk and outcome of COVID-19 infection in sarcoidosis patients

T2 - results of a self-reporting questionnaire

AU - Baughman, Robert P.

AU - Lower, Elyse E.

AU - Buchanan, Mindy

AU - Rottoli, Paola

AU - Drent, Marjolein

AU - Sellares, Jacobo

AU - Terwiel, Michelle

AU - Elfferich, Marjon

AU - Francesqui, Joel

AU - Barriuso Cabrerizo, Maria Rita

AU - Sweiss, Nadera

AU - Martone, Filippo

AU - Al-Hakim, Tamara

AU - Judson, Marc A.

PY - 2020

Y1 - 2020

N2 - Background: It has been suggested that sarcoidosis patients, especially those on immunosuppressive medications, are at increased risk for COVID-19 infection and more severe disease. Methods: A questionnaire was developed in four languages (English, Dutch, Italian, and Spanish). The questionnaire queried whether patients had been infected with COVID-19 and outcome of the infection. Risk factors for COVID-19 infection were collected. Results: A total of 5200 sarcoidosis patients completed the questionnaire with 116 (2.23%) reporting infection and 18 (15.8%) required hospitalization. Increased hazard ratio (HR) for COVID-19 infection were seen for those with a COVID-19 infected roommate (HR=27.44, p

AB - Background: It has been suggested that sarcoidosis patients, especially those on immunosuppressive medications, are at increased risk for COVID-19 infection and more severe disease. Methods: A questionnaire was developed in four languages (English, Dutch, Italian, and Spanish). The questionnaire queried whether patients had been infected with COVID-19 and outcome of the infection. Risk factors for COVID-19 infection were collected. Results: A total of 5200 sarcoidosis patients completed the questionnaire with 116 (2.23%) reporting infection and 18 (15.8%) required hospitalization. Increased hazard ratio (HR) for COVID-19 infection were seen for those with a COVID-19 infected roommate (HR=27.44, p

KW - COVID-19

KW - sarcoidosis

KW - immunosuppression

U2 - 10.36141/svdld.v37i4.10726

DO - 10.36141/svdld.v37i4.10726

M3 - Article

C2 - 33597796

VL - 37

JO - Sarcoidosis Vasculitis and Diffuse Lung Diseases

JF - Sarcoidosis Vasculitis and Diffuse Lung Diseases

SN - 1124-0490

IS - 4

M1 - 2020009

ER -